Pepose JS, et al. - In this randomized, double-masked, parallel-group, vehicle-controlled study, researchers studied the clinical safety and efficiency of povidone-iodine (PVP-I) 0.6%/dexamethasone (DEX) 0.1% ophthalmic suspension in comparison to the vehicle in cases with clinically suspected acute viral conjunctivitis among 132 subjects. They noticed no severe treatment-emergent adverse events (TEAEs). No candidates suspended the treatment due to a TEAE. They noted 56.1% of subjects receiving PVP-I/DEX experienced at least one TEAE vs 43.9% in the vehicle group whereas 78.9% of subjects in the open-label phase encountered at least one TEAE in the masked phase. They overall suggested favorable safety profile of PVP-I/DEX ophthalmic suspension administered for ≤14 days with good tolerability.